These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27543655)

  • 1. Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.
    Phe K; Shields RK; Tverdek FP; Aitken SL; Guervil DJ; Lam WM; Musgrove RJ; Luce AM; Tam VH
    J Antimicrob Chemother; 2016 Dec; 71(12):3585-3587. PubMed ID: 27543655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.
    Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM
    Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.
    Hassan MM; Gaifer Z; Al-Zakwani IS
    Int J Clin Pharm; 2018 Apr; 40(2):444-449. PubMed ID: 29542034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.
    Kwon KH; Oh JY; Yoon YS; Jeong YJ; Kim KS; Shin SJ; Chung JW; Huh HJ; Chae SL; Park SY
    Int J Antimicrob Agents; 2015 Jun; 45(6):605-9. PubMed ID: 25772644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and subclinical acute kidney injury in multidrug-resistant septic patients treated with colistimethate sodium: Incidence and clinical outcomes.
    Thammathiwat T; Tiranathanagul K; Srisawat N; Susantitaphong P; Praditpornsilpa K; Eiam-Ong S
    Nephrology (Carlton); 2020 Jan; 25(1):32-39. PubMed ID: 31509307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
    Hartzell JD; Neff R; Ake J; Howard R; Olson S; Paolino K; Vishnepolsky M; Weintrob A; Wortmann G
    Clin Infect Dis; 2009 Jun; 48(12):1724-8. PubMed ID: 19438394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
    Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
    Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia.
    Korkmaz Ekren P; Töreyin ZN; Berk Takır H; Kalamanoğlu Balcı M; Gaygısız Ü; Gürsel G; Ergan B; Yalçın A; Saltürk C; Aydoğdu M; Ergün R; Güven P; Ulubay G; Gürün Kaya A; Çeltik A; Uluer H; Bacakoğlu F; Sayıner A
    Tuberk Toraks; 2017 Dec; 65(4):271-281. PubMed ID: 29631525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study.
    Rocco M; Montini L; Alessandri E; Venditti M; Laderchi A; De Pascale G; Raponi G; Vitale M; Pietropaoli P; Antonelli M
    Crit Care; 2013 Aug; 17(4):R174. PubMed ID: 23945197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Risk Factors for Colistin-Associated Nephrotoxicity.
    Temocin F; Erdinc S; Tulek N; Demirelli M; Bulut C; Ertem G
    Jpn J Infect Dis; 2015; 68(4):318-20. PubMed ID: 25720641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin-induced Nephrotoxicity in a Tertiary Teaching Hospital.
    Al-Abdulkarim DA; Alzuwayed OA; Al Ammari M; Al Halwan S; Al Maklafi N; Thomas A
    Saudi J Kidney Dis Transpl; 2020; 31(5):1057-1061. PubMed ID: 33229769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate.
    Horcajada JP; Sorlí L; Luque S; Benito N; Segura C; Campillo N; Montero M; Esteve E; Mirelis B; Pomar V; Cuquet J; Martí C; Garro P; Grau S
    Int J Antimicrob Agents; 2016 Dec; 48(6):725-727. PubMed ID: 28128096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system.
    Pogue JM; Lee J; Marchaim D; Yee V; Zhao JJ; Chopra T; Lephart P; Kaye KS
    Clin Infect Dis; 2011 Nov; 53(9):879-84. PubMed ID: 21900484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of intravenous colistin in children.
    Kumar PP; Giri SR; Shaikh FA; Panigrahy N; Chirla D
    Indian Pediatr; 2015 Feb; 52(2):129-30. PubMed ID: 25691180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colistin nephrotoxicity increases with age.
    Balkan II; Dogan M; Durdu B; Batirel A; Hakyemez IN; Cetin B; Karabay O; Gonen I; Ozkan AS; Uzun S; Demirkol ME; Akbas S; Kacmaz AB; Aras S; Mert A; Tabak F
    Scand J Infect Dis; 2014 Oct; 46(10):678-85. PubMed ID: 25073536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients.
    Gauthier TP; Wolowich WR; Reddy A; Cano E; Abbo L; Smith LB
    Antimicrob Agents Chemother; 2012 May; 56(5):2392-6. PubMed ID: 22371891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.